Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib TrialSteffan T. Nawrocki, Kevin R. Kelly, Julian Olea et al.|Clinical Cancer Research|2023Cited by 13
Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple MyelomaKevin R. Kelly, Steffan T. Nawrocki, Kaijin Wu et al.|Blood|2016Cited by 9
A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell LymphomaSwaminathan P. Iyer, Ajit Nair, Auris Huen et al.|Blood|2020Cited by 1
Supplementary Figure S1 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib TrialSteffan T. Nawrocki, Kevin R. Kelly, Julian Olea et al.|Unknown|2023Cited by 0
Supplementary Table S5 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib TrialSteffan T. Nawrocki, Kevin R. Kelly, Julian Olea et al.|Unknown|2023Cited by 0